< BACK

July 27, 2009

Dear Valued Lantheus Medical Imaging Customer,

As part of our ongoing commitment to providing timely updates on the global molybdenum-99
(Mo-99) shortage to our customers, we want to share with you the actions that Lantheus is taking
to find new solutions to ensure a diverse and reliable supply of Mo-99.

As an industry leader, we are doing everything that we can to explore all avenues to address the
global Mo-99 supply challenge, particularly in light of the current shutdown of the NRU reactor in
Canada and the planned shutdown of the High Flux Reactor (HFR) reactor in the Netherlands for
routine maintenance which began on July 18, 2009.

Recently, we announced several new Mo-99 supply agreements that demonstrate our continued
commitment to investing in a supply chain diversification strategy to address the limited and
fragile global Mo-99 supply chain. We remain committed to providing transparent and continuous
communications to our customers, not only during times of acute shortage but also during periods
of relative stability in the market.

• On May 20, 2009, we announced an agreement with NTP Radioisotopes (Pty) Ltd., a
subsidiary of the Nuclear Energy Corporation of South Africa (NECSA), to manufacture and
supply us with an ongoing volume of Mo-99. NTP has, in turn, partnered with Belgian
radiochemical producer IRE to co-supply the Lantheus requirement and thereby maximize
security of ongoing regular supplies of Mo-99 to Lantheus. IRE and NTP have a long and
successful relationship as reliable and consistent suppliers of Mo-99 to key customers.

• On July 9, 2009, we announced the U.S. Food and Drug Administration (FDA) and Health
Canada approvals of our supplemental New Drug Application (sNDA) and Supplemental
New Drug Submission (SNDS), respectively, to qualify the Australian Nuclear Science and
Technology Organisation (ANSTO) as a supplier for low-enriched uranium (LEU) Mo-99 in
the United States and Canada. Both approval notifications were received within one week
of our filing the applications with each organization, underscoring the international
recognition of the impact that the Mo-99 global shortage is having on the healthcare
industry and on the patients who need diagnostic imaging tests.
These approvals are the result of an arrangement between Lantheus and ANSTO announced
on June 13, 2009 in which Lantheus will receive Mo-99 produced from LEU targets in
ANSTO’s new OPAL reactor. It is important to note that with these approvals, Lantheus will
become the first domestic company to offer technetium-99m (Tc-99m) using Mo-99
derived from LEU targets to the U.S. and Canada.
Both the NTP and ANSTO agreements underscore Lantheus’ commitment to investing in a
supply chain diversification strategy to secure a diverse and reliable supply of Mo-99.

• We continue to actively work with suppliers and partners worldwide to maximize our
access to Mo-99 on behalf of our customers and the patients who ultimately benefit from
everything we do. With the Mo-99 we do receive through this time of shortage, we will
continue to allocate it so that we can serve as many customers as possible.

• We continue to work with government officials in the U.S. and Canada to update them on
the current global Mo-99 supply situation and develop innovative solutions in North
America and around the world.

• We continue to collaborate with our valued partners in the medical imaging community and
with global medical isotope production groups to mitigate the impact of sustained outages,
including the Association of Imaging Producers and Equipment Suppliers: European
Industrial Association for Nuclear Medicine and Molecular Healthcare (AIPES), the Society
of Nuclear Medicine (SNM) and the American Society of Nuclear Cardiology (ASNC).

• We are continually investing in our manufacturing capabilities and making real time
changes to our production and distribution schedules to meet the needs of our customers.
The flexibility that Lantheus has created within its supply chain coupled with its own
commitment to maximize supply to the marketplace by making generators available
anytime that Mo-99 is available is serving the marketplace during these times of global
shortage. Lantheus will continue to ensure all available Mo-99 makes it into the
marketplace to be utilized by the customers who need it most.

Lantheus remains committed to serving the needs of the nuclear medicine community by
mitigating the effect of the Mo-99 shortage on nuclear imaging studies and patient care, and
helping to ensure that patients have uninterrupted, timely access to medical imaging procedures
that can diagnose life-threatening conditions. Our goal is to create a future in which patient testing
with Tc-99m is rarely delayed or denied because of Mo-99 supply chain issues. We will continue to
work to identify new and innovative solutions to address the global Mo-99 shortage and will work
with speed and diligence to bring these solutions to the marketplace to address your needs and the
needs of your customers and patients.

Please visit www.lantheus.com for updates regarding Lantheus’ response to the Mo-99 supply
shortage.

Sincerely, 

William Dawes
Vice President
Manufacturing and Supply Chain